Personalized immunotherapy with encapsulated cell technology: Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors

被引：0

作者：

Fernandez, E. ^{[1
]}

Vernet, R. ^{[2
]}

Charrier, E. ^{[3
]}

Migliorini, D. M. ^{[4
]}

Urwyler, M. ^{[2
]}

Belkouch, M-C. ^{[2
]}

Von Rohr, O. ^{[5
]}

Saingier, V. ^{[5
]}

Ancrenaz, V. ^{[5
]}

Grandjean, N. ^{[6
]}

Lafferma, E. ^{[6
]}

Lavalliere, E. ^{[6
]}

Rubin, O. ^{[7
]}

Villard, J. ^{[8
]}

Grogg, J. N. ^{[9
]}

Mach, N. ^{[10
]}

机构：

[1] HUG Hopitaux Univ Geneve, Dept Oncol, Geneva, Switzerland

[2] HUG Hopitaux Univ Geneve, Cell based Immunotherapy Lab, Oncol, Geneva, Switzerland

[3] UNIGE Univ Geneve, Cell Based Immunotherapy Iab, Oncol, Ctr Med Univ CMU, Geneva, Switzerland

[4] Hop Univ Geneve HUG, Oncol, Geneva, Switzerland

[5] HUG Hop Univ Geneve, Cell based Immunotherapy Lab, Oncol, Geneva, Switzerland

[6] HUG Hop Univ Geneve, Clin Res Unit, Oncol, Geneva, Switzerland

[7] HUG Hop Univ Geneve, Clin Cell Therapy Lab, Geneva, Switzerland

[8] Hop Univ Geneve, Clin Cell Therapy Lab, Geneva, Switzerland

[9] MaxiVax SA, R&D, Geneva, Switzerland

[10] HUG Hop Univ Geneve, Oncol, Geneva, Switzerland

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.888

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

762P

引用

页码：S891 / S891

页数：1

共 50 条

[1] Initial safety and feasibility results from a first-in-human clinical trial evaluating a novel magnetic hyperthermia approach for the treatment of metastatic solid tumors
Kraus, Sarah
Tal, Cheri
Shalev, Boaz
Eltanani, Moshe
Rukenstein, Pazit
Arbib, Shir
Eck, Michal
Khandadash, Raz
Atar, Shaul
Cyjon, Arnoldo
Shalev, Ofer
CANCER RESEARCH, 2023, 83 (08)
[2] Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors
Ponomarenko, Dmitry M.
Klimova, Irina D.
Chapygina, Yulia A.
Dvornichenko, Viktoria V.
Zhukova, Natalia V.
Orlova, Rashida V.
Manikhas, Georgy M.
Zyryanov, Alexandr V.
Burkhanova, Lilya A.
Badrtdinova, Irina I.
Oshchepkov, Basile N.
Filippova, Elena V.
Orlov, Sergei V.
Kolesnikov, Sergei I.
Sufianov, Albert A.
Baum, Svetlana R.
Zaitzeva, Olga Y.
Komissarov, Andrey B.
Grudinin, Mikhail P.
Kiselev, Oleg I.
Tsyb, Anatoly F.
Venanzi, Franco
Shcherbinina, Vita
Chursov, Andrey
Gabai, Vladimir L.
Shneider, Alexander M.
ONCOTARGET, 2017, 8 (32) : 53730 - 53739
[3] A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors
Vernet, Remi
Fernandez, Eugenio
Migliorini, Denis
Ancrenaz, Virginie
Charrier, Emily
Belkouch, Marie-Claude
Von Rohr, Olivier
Urwyler, Muriel
De Vito, Claudio
Renaux, Jessica
Villard, Jean
Rubin, Olivier
Grogg, Julien
Mach, Nicolas
CANCER RESEARCH COMMUNICATIONS, 2024, 4 (08): : 2089 - 2100
[4] Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial
Gong, Jifang
Cao, Junning
Zhang, Qingyuan
Xu, Nong
Zhao, Yanqiu
Xing, Baocai
Miao, Zhanhui
Wu, Yilong
Pan, Hongming
Gao, Quanli
Li, Xingya
Liu, Baorui
Li, Wei
Pei, Zhidong
Xia, Hongqiang
Qi, Qinzhou
Dai, Hangjun
Shi, Qingmei
Yang, Jianxin
Li, Jin
Shen, Lin
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (08) : 1897 - 1908
[5] Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial
Jifang Gong
Junning Cao
Qingyuan Zhang
Nong Xu
Yanqiu Zhao
Baocai Xing
Zhanhui Miao
Yilong Wu
Hongming Pan
Quanli Gao
Xingya Li
Baorui Liu
Wei Li
Zhidong Pei
Hongqiang Xia
Qinzhou Qi
Hangjun Dai
Qingmei Shi
Jianxin Yang
Jin Li
Lin Shen
Cancer Immunology, Immunotherapy, 2022, 71 : 1897 - 1908
[6] Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
Tsimberidou, Apostolia M.
Guenther, Kerstin
Andersson, Borje S.
Mendrzyk, Regina
Alpert, Amir
Wagner, Claudia
Nowak, Anna
Aslan, Katrin
Satelli, Arun
Richter, Fabian
Kuttruff-Coqui, Sabrina
Schoor, Oliver
Fritsche, Jens
Coughlin, Zoe
Mohamed, Ali S.
Sieger, Kerry
Norris, Becky
Ort, Rita
Beck, Jennifer
Vo, Henry Hiep
Hoffgaard, Franziska
Ruh, Manuel
Backert, Linus
Wistuba, Ignacio I.
Fuhrmann, David
Ibrahim, Nuhad K.
Morris, Van Karlyle
Kee, Bryan K.
Halperin, Daniel M.
Nogueras-Gonzalez, Graciela M.
Kebriaei, Partow
Shpall, Elizabeth J.
Vining, David
Hwu, Patrick
Singh, Harpreet
Reinhardt, Carsten
Britten, Cedrik M.
Hilf, Norbert
Weinschenk, Toni
Maurer, Dominik
Walter, Steffen
CANCER IMMUNOLOGY RESEARCH, 2023, 11 (07) : 925 - 945
[7] PRELIMINARY SAFETY, EFFICACY AND PHARMACOKINETIC RESULTS OF THE EP4 ANTAGONIST INV-1120 FROM A FIRST-IN-HUMAN STUDY IN SUBJECTS WITH ADVANCED SOLID TUMORS
Sarantopoulos, John
Patnaik, Amita
Zeng, Zhaopie
Nippgen, Johannes
Sun, Yongkui
Zhu, Yi
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A625 - A625
[8] First-in-human phase I trial of NHS-IL12 in advanced solid tumors
Kim, Joseph W.
Heery, Christopher Ryan
Bilusic, Marijo
Singh, Nishith K.
Madan, Ravi A.
Sabzevari, Helen
Schlom, Jeffrey
Gulley, James L.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[9] A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
Hong, David S.
Kurzrock, Razelle
Supko, Jeffrey G.
He, Xiaoying
Naing, Aung
Wheler, Jennifer
Lawrence, Donald
Eder, Joseph Paul
Meyer, Colin J.
Ferguson, Deborah A.
Mier, James
Konopleva, Marina
Konoplev, Sergej
Andreeff, Michael
Kufe, Donald
Lazarus, Hillard
Shapiro, Geoffrey I.
Dezube, Bruce J.
CLINICAL CANCER RESEARCH, 2012, 18 (12) : 3396 - 3406
[10] Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors
Creelan, Ben C.
Gabrilovich, Dmitry I.
Gray, Jhanelle E.
Williams, Charles C.
Tanvetyanon, Tawee
Haura, Eric B.
Weber, Jeffrey S.
Gibney, Geoffrey T.
Markowitz, Joseph
Proksch, Joel W.
Reisman, Scott A.
McKee, Mark D.
Chin, Melanie P.
Meyer, Colin J.
Antonia, Scott J.
ONCOTARGETS AND THERAPY, 2017, 10 : 4239 - 4250

← 1 2 3 4 5 →